KRAS G12D drug race intensifies after 40 years of failed development
AI Summary- KRAS G12D has become a major focus of global pharmaceutical investment.
- Drug-development efforts targeting the mutation resisted success for more than 40 years.
- Multi-billion-dollar deals, late-stage trials and regulatory filings are advancing the race.